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Abstract
Chloroquine (CQ) resistant vivax malaria is spreading. In this case, Plasmodium vivax infections during pregnancy
and in the postpartum period were not satisfactorily cleared by CQ, despite adequate drug concentrations. A
growth restricted infant was delivered. Poor susceptibility to CQ was confirmed in-vitro and molecular genotyping
was strongly suggestive of true recrudescence of P. vivax. This is the first clinically and laboratory confirmed case of
two high-grade CQ resistant vivax parasite strains from Thailand.
Background
Chloroquine (CQ) remains the recommended first-line
treatment for Plasmodium vivax globally except for
Indonesia, Papua New Guinea, the Solomon Islands and
Vanuatu where widespread CQ resistance prompted a
change in treatment policy [1,2]. Clinical monitoring of
CQ efficacy is confounded by relapses derived from the
activation of hypnozoites (dormant hepatic forms char-
acteristic of P. vivax), making it difficult to categorize
post-treatment episodes as recrudescences, re-infections
or relapses [3]. Moreover measurement of the intrinsic
sensitivity to CQ has been hampered by the difficulty to
maintain P. vivax in culture. Nonetheless cases of CQ-
resistant P. vivax have been reported from all continents
where malaria is endemic, but never in pregnancy [1].
Previous clinical studies in the non pregnant Thai popu-
lation where CQ was combined with primaquine did
not show cases of highly suspect CQ resistant vivax
[4-6]. Combined clinical and laboratory data from a clo-
sely monitored Karen pregnant woman on the western
border of Thailand highly indicative of CQ resistance by
molecular genotyping is presented in this report.
Case presentation
A 38 year-old pregnant Karen woman (blood group B,
G6PD level normal and HIV negative) in her third preg-
nancy registered at a gestational age of 20
+5 weeks (con-
firmed by abdominal ultrasound) [7]. She lived and
worked in the forests on the Thai-Myanmar border and
provided written informed consent to participate in a
“postpartum susceptibility to malaria” study approved by
the Ethics Committees of Oxford University (OxTREC
(002_007) and Mahidol University (MUTM 2007-023)
which included repeated blood sampling and publication
o fa n yd a t a .S h eg a v eb i r t ht oag r o w t hr e s t r i c t e dl i v e
born singleton boy without congenital abnormality of
2,540 (±10) grams at a gestational age of 41
+1 weeks
(<10
th percentile) on 19 December 2008. On the day of
registration (D0) she presented with fever and was diag-
nosed with P. vivax malaria on the presence of asexual
forms in peripheral blood (parasitaemia 9294/μL). Treat-
ment was with CQ (25 mg base/kg total dose, Govern-
ment Pharmaceutical Organization, Thailand) as per
standard protocol. Over the following 227 days she was
treated eight times for recurrent P. vivax parasitaemic
episodes.
Methods
Parasite species diagnosis of each episode was deter-
mined by microscopic examination of Giemsa-stained
blood films. This was later confirmed by nested PCR [8]
for the episodes that occurred after D21, when suspicion
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parasites were genotyped for three polymorphic mar-
kers: defined polymorphic regions in the genes encoding
for the circumsporozoite surface protein (Pvcs), the mer-
ozoite surface protein 1 (Pvmsp1) or the merozoite sur-
face protein 3a (Pvmsp3-a) [3,9,10] and for point
mutations or copy number variation in the multi drug
resistance gene 1, Pvmdr1 [11]. Blood samples were also
obtained from the placenta (including by mechanical
extraction), umbilical cord and from the infant. Histo-
pathologic analysis of a placenta biopsy was performed
on Giemsa-stained cryo-sections.
The intrinsic ex vivo sensitivity assays were carried out
for chloroquine, artesunate, piperaquine, mefloquine and
amodiaquine on a leukocyte-depleted P. vivax isolate
[12]. The pre-dosed plates employed for these assays
were quality assured using a Plasmodium falciparum
cloned line (PfK1). Dose response curves and IC50 (50%
inhibitory concentration) values were calculated by
fitting the data to a sigmoidal inhibitory E-max pharma-
codynamic model using WINNONLIN Ver 4.1 (Phar-
sight Corporation). The assays were duplicated and the
data confirmed independently by three experienced
microscopists.
Serum CQ and desethylchloroquine (DECQ) concen-
trations were measured using solid-phase extraction and
liquid chromatography coupled with UV-detection [13].
Results
O v e rt h ec o u r s eo f2 2 7d a y st h i sw o m a nw a ss e e n2 6
times (see Figure 1). The parasitological and laboratory
findings for the samples collected from the pregnant
woman are summarized in Figure 1. The persistence of
P. vivax (parasite count 750/μl, non-symptomatic) on
D7 post CQ administration prompted a second CQ
course but parasites were still present in the blood on
her next visit (D21) (parasite count 850/μl, non-sympto-
matic). Chloroquine was administered again (3
rd course).
Figure 1 Plasmodium vivax infections in a Karen woman observed over 227 days pregnancy and postpartum period.T h eP. vivax
genotypes (indicated by bars of different colours) are based on polymorphisms in 4 genes (Pvcs, Pvmsp1, Pvmsp3-a, and Pvmdr1). The
treatments administered are indicated on top. PCR spots are indicated with black (negative) and grey (positive) dots. The intrinsic sensitivity
profile of P. vivax isolate to a range of standard antimalarials (chloroquine (QC), artesunate (AS), piperaquine (PPQ), mefloquine (MQ) and
amodiaquine (AMQ)) is shown for the parasites collected on D31. The in vivo serum concentrations of CQ + desethylchloroquine (DECQ) are
indicated for the samples collected on D31, D71 and D143.
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27500/μL) were present on D31, and a complete super-
vised course of CQ was given. An asymptomatic P.
vivax parasitaemia on D49 (parasite count 500/μL)
pressed the administration of a fifth course of CQ.
When vivax parasites re-appeared on D71 (parasite
count 10,000/μL, symptomatic) the women was given a
course of dihydroartemisinin (DHA) - piperaquine
(PPQ), (6.75 mg/kg DHA and 54 mg/kg PPQ, 3 days,
Holley Pharm, Peoples Republic China), the most effec-
tive treatment against uncomplicated vivax malaria in
West Papua[14], and parasites were undetectable by
microscopy over the next five visits (D92-D119). A para-
sitaemic episode on D126 (parasite count 1000/μL, non-
symptomatic) close to the expected delivery date was
treated with CQ. But on delivery (D143) parasites were
still detected in the mother’s peripheral blood (parasite
count 500/μl, non-symptomatic) and placenta (detected
by PCR of placental blood). Placenta histologic findings
were subtle: rare parasites, very mild inflammatory infil-
trate and scant pigment deposition in the intervillous
space. This infection was treated with artesunate (AS) (2
mg/kg/day, 7 days, Guilin, PRC) and parasites were not
detected in blood smears taken on subsequent visits
(D150 - D199), but on D206, 63 days postpartum an
asymptomatic infection (parasite count 4,000/μl) was
detected again. This was treated with DHA-PPQ and
primaquine (PQ) (22.5 mg base/day for 14 days, GPO,
Bangkok, Thailand). The parasites were promptly
cleared and the blood smear remained negative until the
end of the follow-up which was three months post-par-
tum (D227). There were no parasites found in the cord
blood or in the infant, who remained negative thereafter.
Combined CQ + DECQ serum concentrations
obtained at three of the clinical episodes (D31 = 20.6,
D71 = 10.8 and D143 = 7.9 ng/ml) indicated adequate
drug exposure and were around the 15 ng/ml serum
threshold considered therapeutic against CQ-susceptible
parasites[15]. Blood samples were also collected on
these days for ex vivo sensitivity assays but only one
(D31) harboured parasites at a developmental stage sui-
table for meaningful analysis [12]. The ex vivo suscept-
ibility profile clearly indicated P. vivax with reduced
sensitivity to CQ (IC50 = 270 nM) though not to the
other anti-malarials tested (Figure 1).
PCR analysis confirmed the microscopic diagnoses and
interestingly two additional sub-microscopic infections
(D119, D199) were observed the week before they were
detected microscopically. Genotyping revealed that the
patient was successively infected by three distinct P.
vivax populations (Figure 1 and Table 1). Parasites from
D21-D49 were of similar genotype to those of D126-
D143 but differed from the two distinct populations pre-
sent on D71 and D206. All parasites had a single copy
of Pvmdr1 and a T958M mutation but for those from
D21-D49 and D126-D143 an additional Y976F mutation
was observed.
Conclusion
This woman had multiple P. vivax episodes over a 227-
day period during pregnancy and post-partum, charac-
terized by repeated recurrences of P. vivax parasites fol-
lowing CQ treatment and resulting in a growth
restricted neonate. The in vivo observations of P. vivax
recurrences were associated to an ex vivo drug sensitiv-
i t ya s s a ys h o w i n gaC QI C 50 of 270 nM. This value is
indicative of high-grade CQ vivax resistance as it
exceeds recently published IC50 medians for CQ of 37
nM for Thai (CQ sensitive) and 114 nM for Papuan
(CQ resistant) isolates [12]. Indeed on two occasions
(D31 and D71) each with a different genotype the para-
sitaemia increased substantially despite the presence of
therapeutically adequate drug concentrations. The com-
bined CQ+DECQ concentrations were similar to what
has been reported for resistant vivax cases in a study in
Myanmar [16]. It is interesting that the Pvmdr1 Y967F
mutation was found in the parasites from two genotypi-
cally distinct episodes (Genotypes A and B). This puta-
tive marker of CQ resistant vivax was relatively rare
(only 20%) in isolates from the Thai-Myanmar border
[17], but was present in 97% of the isolates from West
Papua where CQ vivax resistance is widespread[11].
This could imply that there are at least two strains of
chloroquine resistant parasites circulating in this area.
The CQ-resistant P. vivax in this Karen woman might
have been acquired in Myanmar where she worked in
the forests during her pregnancy, but she could have
also acquired the infection in Thailand where she
resides. Irrespective of its origin the fact that CQ-resis-
tant vivax malaria appears to be spreading is a matter
for concern.
Evidence based treatment guidelines for CQ resistant
vivax infections are urgently needed to prevent repeated
dosing of an ineffective drug, a practice known to
enhance the selection and spread of resistant parasites.
H o w e v e r ,t h ec h o i c eo fs a f ea n de f f e c t i v ed r u g st o
replace chloroquine is very limited. Some artemisinin-
combinations, such as DHA-PPQ or artesunate-meflo-
quine, are effective against P. vivax [1], but artemisinins
are contraindicated in the first trimester and prima-
quine, the sole drug effective against hypnozoites, is also
contraindicated in pregnant women. In South East Asia,
P. vivax is resistant to sulphadoxine-pyrimethamine
[18], a drug considered to be safe during pregnancy.
Careful monitoring of the efficacy of CQ in the treat-
ment of P. vivax in this region is needed especially in
pregnant women to reduce the harmful effects on
mothers and infants [19].
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Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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